Good skin tolerance.
Straightens - Reduces excess sebum - Refines skin texture - Unclogs the pores
A cleansing cream that helps remove spots and blackheads.
KERACNYL GLYCOLIC+ cream targets and helps remove blackheads and blemishes on young and adult acne-prone skin.
It also combats shine by regulating excessive sebum production and smoothing the skin.
Applied daily after cleansing the skin, it is an excellent base for makeup.
Thanks to the action of glycolic acid, KERACNYL GLYCOLIC + cream targets blackheads in young or adult acne-prone skin and promotes their disappearance from 2 days*.
• HELPS remove blackheads : GLYCOLIC ACID, a keratolytic active ingredient, unclogs pores and gently exfoliates skin
• HELPS rebalance bacterial flora and remove spots the natural extract MYRTACINE®
• CAN BE USED as a makeup base
*Clinical tolerability and efficacy study. % satisfied at T2 days in 39 adult/adolescent subjects. 2 applications per day.
• Once or twice a day on dry skin, after cleansing with KERACNYL Foaming Gel
• NON-COMEDOGENIC
• Designed to minimise the risk of allergic reactions
Precaution to use :
• Avoid contact with eyes.
• Limit exposure to the sun while using the product or use sun protection
• If you experience discomfort, it is recommended that you apply the product every other day
• Do not use on irritated skin
An active ingredient that helps unclog pores
1st innovative active ingredient from Pierre Fabre biotechnology, Celastrol, is of 100% natural origin and produced through the cultivation of plant cells. This soothing active ingredient directly targets keratinocytes to reduce the appearance of plaques and improve skin appearance
• -45%¹ reduction in sebum secretion
• 87%² (% satisfied) : blemishes are visibly reduced after 8 days
• 97,4%² (% satisfied) : skin is smoother
• Skin is mattified from the first application³
¹Clinical tolerability and efficacy study in 39 subjects (adults/adolescents); 2 applications per day (morning and evening). Instrumental measurement with a sebum meter. Result at T 8days
²Clinical tolerability and efficacy study. % satisfied at T8 days in 39 adult/adolescent subjects. 2 applications per day.
³Clinical study conducted on 20 subjects, single application
